The most common adverse events are gastrointestinal: nausea (occurring in 12-33% of subjects depending on dose), diarrhea, constipation, and decreased appetite
Materials and methods Cell culture and characterization Human iPSCs (gifted from Bonyakhteh Stem Cell Research Center, Tehran, Iran) were maintained on mitomycin C-arrested mouse embryonic fibroblasts in an undifferentiated state 21 in DMEM/F12 (Gibco by Life Technologies, Paisley, Scotland, UK) medium supplemented with 1% non-essential amino acids, 20% knockout serum replacement, 4 ng/ml bFGF (all from Sigma-Aldrich Chemie GmbH, Steinheim, Germany), and 1 mM L-glutamine (Sigma-Aldrich, St
Main Research Findings 1) Administration of cagrilintide to overweight and obese patients was a well tolerated treatment that led to a significant reduction in body weight
The dominant driver is reduced caloric intake
There are moments when an entire field quietly crosses a threshold
doi:10.3390/ijms19071987 Pickart L, Margolina A
